Events

Kevin Outterson, Executive Director of CARB-X, will be giving the keynote Address on November 7th, titled "A vision for a health antibiotic R&D ecosystem".  Outterson will also be participating on a panel titled "Analyzing the potential impact of current commercial and “pull” initiatives" on November 7th. Karen Gallant, Deputy Executive Director of CARB-X, will be […]

This webinar by Paul Hergenrother (Department of Chemistry and the Institute for Genomic Biology University of Illinois, US) will detail his research group's efforts to understand compound accumulation in the Gram-negative ESKAPE pathogens. Emphasis will be placed on the practicality, actionability, and translatability of this information, specifically, the use of accumulation rules to convert high-value […]

Presenters include Karen Gallant, Deputy Executive Director of CARB-X. Few technologies have the potential to disrupt and eliminate infectious disease and viral infections– but gene editing, CRISPR in particular, is a latent technology that could change biotech – and we’re just seeing the beginning of what effect it could have on the world. With scientific […]

Kevin Outterson, Executive Director of CARB-X, is participating in a special panel discussion titled "When antibiotics fail: An international conversation about the worrisome evidence of impact and what can be done". During this session, a panel of international experts will discuss the findings from a new report by the Council of Canadian Academies and discuss […]

Presenters include Kevin Outterson, Executive Director of CARB-X, and Erin Duffy, CARB-X Chief of Research and Development. The FDA, IDSA, NIAID and Pew are co-sponsoring this workshop to focus on Enhancing the Clinical Trial Enterprise for Antibacterial Drug Development in the United States. This workshop will bring together a diverse array of subject matter experts […]

In this webinar our moderator Caroline Purslow (Nesta Challenges) will welcome three speakers. Till Bachmann (University of Edinburgh) will give an overview of recent advances in AMR diagnostics development. He will discuss: State of the art approaches for diagnosing infections and AMR Pipeline of promising tests Challenges of adoption Amrita Sukrity (SpotSense) will draw from […]

Speakers include Kevin Outterson, Executive Director of CARB-X. The rise of antimicrobial resistance and the corresponding lack of novel antibiotic development impacts the ability of physicians to provide appropriate care for patients. The greatest barriers to a robust antibiotic ecosystem are low return on investment (ROI) and limited market opportunities, in part due to payment […]

Moderator: Kevin Outterson, Executive Director, CARB-X, Professor of Law, Boston University Panel: Lars Rebien Sorensen, Chairman of the Novo Nordisk Foundation and Novo Holdings Jeremy Farrar, Director, Wellcome Trust Dr. Malin Grape, Head of Antibiotics Unit, The Public Health Agency of Sweden Thomas Cueni, Director General, IFPMA Jayasree K. Iyer, Executive Director, Access to Medicine Foundation […]

In this webinar, the following aspects will be presented: What are the most common techniques used to measure the extent of the risk of selecting for resistance when using a novel direct-acting antibacterial. What are the advantages and limitations of these techniques? What are some techniques that may be used to understand the origins of […]

In this webinar, the following aspects will be presented: Discovery and early development of “non-traditional” antibacterial approaches is a noticeable trend in the pre-clinical global pipeline These approaches include anti-virulence strategies, microbiome-modifying therapies, phages and others such as nanoparticles, immunotherapy and drug-resistance modulation Some of these approaches require novel preclinical efficacy models to predict clinical […]